A major European research initiative has uncovered a concerning prevalence of undiagnosed liver fibrosis, revealing that many individuals living with the condition are entirely unaware of their status until the damage becomes irreversible.
The findings, part of the LiverScreen project and published in The Lancet, highlight a critical gap in early detection. According to the study, which analyzed approximately 30,000 individuals over the age of 40 across nine European nations, about 1.6% of the general population has previously undiagnosed liver fibrosis. This suggests that roughly one in every sixty people may be living with the condition without knowing it.
The research utilized FibroScan, a non-invasive technique that measures liver stiffness to estimate fibrosis levels without the require for a surgical biopsy. During the initial screening phase, 4.6% of participants showed high results, prompting referrals for specialized hospital confirmation. Of those evaluated in a clinical setting, 32% were confirmed to have chronic liver disease with fibrosis.
Medical experts warn that the “silent” nature of the disease is its most dangerous characteristic. Dr. Pere Ginés, a senior consultant in Hepatology at the Hospital Clínic de Barcelona, noted that “the liver disease develops very slowly, even over 25 or 30 years.” Because patients often lack symptoms and standard blood tests may fail to detect the issue, many do not seek medical attention until the disease has progressed significantly.
The study indicates that liver fibrosis—the result of chronic liver damage—is more prevalent among specific high-risk groups, including those with obesity, diabetes, or hypertension. This underscores the importance of targeted screening to prevent the progression toward more severe conditions, such as cirrhosis or liver cancer.
Rafael Bañares, Professor of Medicine at the Complutense University of Madrid and president of the Spanish Association for the Study of the Liver, emphasized that identifying asymptomatic patients is vital for improving long-term outcomes. “Detecting patients before they develop symptoms allows us to intervene so that the disease does not advance and require hospitalizations with delicate prognoses and very complex treatments,” Bañares stated.
These findings suggest a pressing need for updated screening protocols, as early intervention can fundamentally change the trajectory of the disease before it reaches an irreversible stage.
